Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Diabetic Neuropathy Treatment Market

Diabetic Neuropathy Treatment Market Share

Report ID: GMI10259
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Diabetic Neuropathy Treatment Market Share

The diabetic neuropathy treatment industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel therapeutics with improved efficiency and cost-effectiveness are key market strategies for diabetic neuropathy drugs manufacturers, driving competition and innovation in the industry. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for novel diabetic neuropathy treatment.

Diabetic Neuropathy Treatment Companies

Some of the eminent market participants operating in the diabetic neuropathy treatment industry include:

Abbott
Boehringer Ingelheim GmbH
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd
Janssen Pharmaceuticals, Inc
Lupin Pharmaceuticals
MEDA Pharma GmBH & Co. KG
Pfizer Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global diabetic neuropathy treatment industry was valued at USD 4.3 billion in 2023 and is anticipated to register 7.9% CAGR between 2024 and 2032 due to the increasing prevalence of diabetes and advancements in therapeutic and diagnostic techniques.

The peripheral neuropathy segment in the diabetic neuropathy treatment market held 45.4% revenue share in 2023 due to its prevalence among diabetic patients and the availability of various therapeutic options, attracting both patients and health professionals.

Asia Pacific diabetic neuropathy treatment market accounted for USD 1.9 billion in 2023, driven by the high diabetes prevalence and increased awareness about early diagnosis and treatment of diabetic neuropathy.

Abbott, Boehringer Ingelheim GmbH, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd, Janssen Pharmaceuticals, Inc, Lupin Pharmaceuticals, MEDA Pharma GmBH & Co. KG, and Pfizer Inc.